These results show that cutaneous vasculitis in rheumatoid arthritis is associated with selective impairment of complement-mediated monocyte phagocytosis, which does not appear to result from receptor blockade by immune complexes.
Introduction
Cutaneous vasculitis in rheumatoid arthritis is associated with hypocomplementaemia,' increased complement consumption,2 large 19S IgM-containing circulating immune complexes,3 and deposition of complement-containing immune complexes in small arterioles. 4 The episodic nature of clinical manifestations of vasculitis in rheumatoid arthritis suggests the possibility of intermittent saturation of immune clearance mechanisms. The cells thought to be responsible for clearance of circulating immune complexes are the mononuclear phagocytes of the spleen and liver.5 As part of an investigation of mononuclear phagocyte function in rheumatoid arthritis we performed invitro measurements of monocyte phagocytosis in patients with uncomplicated rheumatoid arthritis, patients with rheumatoid cutaneous vasculitis, and normal controls.
Subjects and methods
Mononuclear cells were separated from 10 ml of venous blood using a density gradient,6 washed, and resuspended in Hanks's balanced salt solution plus 0-1% gelatin. The concentration of monocytes present was determined using a rapid Coulter sizing technique7 validated by comparison with differential cell counts performed with non-specific esterase stains.8
Heat-killed yeast were preopsonised in bulk, resuspended to 107/ml, and stored in aliquots in liquid nitrogen. Direct immunofluorescence verified that Candida albicans opsonised in fresh human serum was coated with complement (C3) and immunoglobulins (IgG, IgA, and IgM) 
Results
In the initial study using C albicans opsonised with both C3 and immunoglobulins there was no difference in the rate constant Kbetween normal controls and patients with uncomplicated rheumatoid arthritis, but K, was significantly reduced (p <001, rank sum test) in the patients with active vasculitis (fig 1) . In subsequent studies, in which the rate constants for C3-mediated uptake (KC) and Fc-mediated uptake (KFC) were measured separately, no change was found in KFC in the patients with vasculitis compared with the normal controls (fig 2) but Kc was significantly reduced (p <001, rank sum test) (fig 3) . In three subjects whose vasculitis was judged to be clinically inactive Kc was in the normal range. All patients in whom Kc was low had low serum C3 concentrations, while the three subjects with inactive vasculitis and normal K, had normal serum C3 concentrations ( The clotting values of 50 patients with glomerulonephritis were examined. Three different coagulation groups were recognised: those with normal clotting values (group 1); those with high concentrations of factor VIII but otherwise normal clotting results (group 2); and patients who showed the presence of an activator of the intrinsic coagulation pathway, indicated by the presence of a short activated partial thromboplastin time or the ability of patients' plasma to shorten control clotting time in mixing studies (group 3). Patients in group 2 either had a uniform rise in all three components of the factor VIII molecule or a disproportionately higher concentration of factor-VIII-related antigen. In contrast, the level of VIII clotting activity in patients in group 3 was always higher than concentrations of either VIIIAg or VIIIWF. A significantly high incidence of thrombotic complications was observed in patients in group 3 but in none of the patients in either group 1 or group 2. Impaired renal function was more common in patients in groups 2 and 3, with higher mean serum creatinine concentrations in those in group 3.
Patients with glomerulonephritis who have a short partial thromboplastin time with kaolin or who shorten control clotting time form a subgroup in whom hypercoagulation could adversely affect the course of their disease. The value of antiplatelet or anticoagulant treatment in these patients needs to be explored.
Introduction
The role of the coagulation process in the pathogenesis of glomerulonephritis and its complications have become increasingly recognised. Experimental evidence aInd findings on pathological examination of kidneys from patients with glomerulonephritis suggest that local intravascular coagulation plays an important role in the progression of the renal disease.' In these patients the presence of a systemic hypercoagulable state may contribute to the deterioration of renal function and may be associated with a high incidence of thrombotic complications. In patients with established nephrotic syndrome a high incidence of thromboembolic phenomena has been reported.2 The observed high concentrations of factors V and VIII3 and low concentrations of antithrombin III4 are thought to be important in the pathogenesis of this complication. The clotting values of other patients with glomerulonephritis have, however, received little attention in recent reports. This paper reports an investigation of the clotting values of 50 patients with glomerulonephritis and establishes the incidence of a coagulation accelerating factor recognisable in vitro and its possible influence on the clinical course of these patients.
Patients and methods
Fifty patients (24 men, 26 women) aged from 12 to 78 years (mean 37±16) were examined. In all patients the diagnosis of glomerulonephritis was confirmed by renal biopsy. Two additional groups served as controls: (a) 20 healthy individuals (medical and laboratory personnel), and (b) 70 age-and sex-matched inpatients with various medical disorders. These inpatients included 20 patients with renal disease not characterised by glomerulonephritis but with a comparable degree of renal impairment as the study group and 50 with various disorders such as ischaemic heart disease, cerebrovascular accidents, chronic bronchitis, collagen disease, malignant lymphoma, and thyroid disease. None of the control patients were known to have a haemorrhagic tendency.
Blood was collected in 1/10 volume 3 8% trisodium citrate. Plateletpoor plasma was obtained by centrifugation at 2000 g for 15 minutes. Prothrombin, thrombin, and Stypven times were measured by standard methods. Partial thromboplastin time with kaolin (PTTK) was measured by incubating 0-1 ml of plasma with 0-05 ml kaolin 50 mg/ml and 0-05 ml Platelin (General Diagnostics) for 3 minutes
